Indications for use:
Diabetes mellitus, type I (insulin-dependent); diabetes mellitus, type II (insulin-independent): the stage of resistance (resistance) to oral (taken by mouth) hypoglycemic (blood sugar lowering) agents, partial resistance to these products (combination therapy), intercurrent (complicating the course of diabetes mellitus) diseases, operations (monotherapy / treatment with one product / or combination therapy), pregnancy (if diet therapy is ineffective).
Ultralente (Ultralente) method of administration and doses:
The dose is selected by the doctor strictly individually. The drug is injected deep subcutaneously. It should not be injected into the same place.
Before use, the vial is gently shaken in order to completely mix the insulin with the solvent. The appropriate dose of the product is immediately drawn into the syringe and administered to the patient.
In type I diabetes, ultralente is used as basal insulin (the primary treatment) in combination with a fast-acting insulin product. In type II diabetes mellitus, ultralente can be used both as monotherapy and in combination with fast-acting insulins.
At a daily dose exceeding 0.6 U / kg of body weight, insulin must be administered in the form of 2 or more injections at different sites.
Patients receiving 100 IU or more per day should be hospitalized when replacing insulin.
The transition from one insulin product to another should be carried out under the control of blood glucose levels.
Alpha-adrenergic blockers, oxytetracyclines, strophanthin, salicylates increase the activity of endogenous (formed in the body) insulin. Oral contraceptives and glucocorticoids reduce the activity of insulin. The simultaneous use of alcohol or the appointment of beta-adrenergic blockers can lead to hypoglycemia (low blood sugar levels). Simultaneous use of thiazide diuretics can cause hyperglycemia (increase in blood sugar levels). The dose of insulin must be adjusted in the following cases: infectious diseases, surgical interventions, pregnancy, thyroid dysfunction, Addison’s disease (decreased adrenal function), kidney failure and diabetes mellitus in people over 65 years of age.
Ultralente (Ultralente) side effects:
Hypoglycemic (accompanied by a decrease in blood sugar) conditions (pallor, sweating, palpitations, tremor / trembling of the limbs / – from moderate to convulsions); hypoglycemic precoma (incomplete loss of consciousness – the initial stage of coma development, characterized by the preservation of pain and reflex reactions) and coma (complete loss of consciousness, characterized by a complete absence of body reactions to external stimuli); hyperemia (redness) and itching at the injection site in the first weeks of treatment. Rarely – allergic reactions in the form of skin rash, angioedema, laryngeal edema, anaphylactic shock. With prolonged use at the injection site – lipodystrophy (decrease in the volume of adipose tissue in the subcutaneous tissue).